Yoğunluk ayarlı radyoterapi yapılan meme kanseri hastalarında, tiroid bezinde ikincil malignite gelişme riski tahmini

Year 2018, Volume: 11 Issue: 3, 295 - 302, 25.12.2018

Songül Barlaz Us , Aytül Kanat Yusuf Tolga Şanlı

https://doi.org/10.26559/mersinsbd.414986

https://izlik.org/JA97DT74DB

Abstract

Amaç: Meme radyoterapisinden (RT) sonra tiroid bezinde
radyasyona bağlı ikincil malignite gelişme riski artmaktadır. Bu çalışmada yoğunluk
ayarlı radyoterapi (Intensity modulated radiotherapy-IMRT) yapılan meme kanseri
hastalarında tiroid bezi malignitesi gelişme riskinin değerlendirilmesi
amaçlanmıştır. Yöntem: Çalışmada
total mastektomi ve meme koruyucu cerrahi sonrası IMRT uygulanan 70 meme
hastası değerlendirilmiştir. Hastalarda tiroid bezinde ikincil malignite
gelişme riski, ERR (Estimating relative risk-tahmini rölatif risk) modeli
kullanılarak hesaplanmıştır. Bulgular:
Supra klaviküler bölgenin, RT alanına dahil edildiği hastalarda (Grup-1), ERR
değeri supraklaviküler bölgenin RT alanına dahil edilmediği hastalardan
(Grup-2) daha yüksek olduğu görülmüştür. ERR değerleri, yaş arttıkça
eksponansiyel olarak azalmıştır. Gruplar arasındaki tiroid bezi dozları farklı
olmasına rağmen, yaş arttıkça iki gruptaki ERR değerleri birbirine yaklaşmıştır.
Sonuç: Meme IMRT’si sonrası, tiroid
bezinde ikincil malignite gelişme riski, genç hastalarda daha yüksektir. Bu
nedenle genç hastalardaki RT uygulamalarında sağlam ve geçerli risk
değerlendirmesi tavsiye edilmektedir. 

Keywords

Meme IMRT , tiroid bezi , ikincil malignite riski

References

• 1. Adam D et al. Volumetrıc-Modulated Arc Therapy Vs. 3d-Conformal Radiotherapy For Breast Cancer. Romanian Reports in Physics. 2015; 67(3): 978–986.
• 2. Erpolat OP et al. The evaluation of the feasibility of carotid sparing intensity modulated radiation therapy technique for comprehensive breast irradiation. Physica Medica 2017; 36: 60–65.
• 3. Muralidhar KR et al. Intensity modulated radiotherapy versus volumetric modulated arc therapy in breast cancer: A comparative dosimetric analysis . Int J Cancer Ther Oncol 2015;3(2):1-6.
• 4. Lee B et al. Radiotherapy-induced secondary cancer risk for breast cancer: 3D conformal therapy versus IMRT versus VMAT. J Radiol Prot 2014;34:325-31.
• 5. Abo-Madyan Y et al. Second cancer risk after 3D-CRT, IMRT and VMAT for breast cancer. Radiother Oncol 2014; 110:471-6.6. ICRP Recommendations of the International Commission on Radiological Protection (Users Edition). ICRP Publication 103 (Users Edition). Ann. ICRP 2007;37:2-4.
• 7. BEIR, Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII, Phase 2. National Academy of Science, Washington, DC, 2006.
• 8. United Nations Scientific Committee on the Effects of Atomic Radiation, Sources and Effects of Ionizing Radiation: UNSCEAR Report to the General Assembly, with Scientific Annexes, United Nations, New York, 2006.
• 9. Lee WC. Excess Relative Risk as an Effect Measure in Case-Control Studies of Rare Diseases. PLoS ONE 2015;10(4):1-9.
• 10. Johansen S et al. A planning comparison of dose patterns in organs at risk and predicted risk for radiation induced malignancy in the contralateral breast following radiation therapy of primary breast using conventional, IMRT and volumetric modulated arc treatment techniques. Acta Oncol 2009;48(4):495–503.
• 11. Rooney KP et al. Intensity modulated radiotherapy in locally advanced thyroid cancer: outcomes of a sequential phase I dose-escalation study. Radiother Oncol 2018;xxx:1-6.
• 12. Johansen S et al. Estimated risk for secondary cancer in the contra-lateral breast following radiation therapy of breast cancer. Acta Oncologica 2008;47(3):391-396.
• 13. Schonfeld SJ and Lee CA. Berrington de Gonzalez A. Medical Exposure to Radiation and Thyroid Cancer. Clinical Oncology 2011;23:244-250.
• 14. Athar BS and Paganetti H. Comparison of second cancer risk due to out-of-field doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans. Radiother Oncol. 2011; 98(1): 87–92.
• 15. Xu XG et al. A review of dosimetry studies on external-beam radiation treatment with respect to second cancer. Phys. Med. Biol. 2008;53:193-241.
• 16. Bazire L et al. Risks of second malignancies after breast cancer treatment: Long-term results. Cancer/Radiothérapie 2017;21:10–15.
• 17. Donovan EM et al. Second Cancer Incidence Risk Estimates using BEIR VII Models for Standard and Complex External Beam Radiotherapy for Early Breast Cancer. Med Phys. 2012;39(10): 5814–5824.
• 18. Wolny-Rokicka E et al. Thyroid Function after Postoperative Radiation Therapy in Patients with Breast Cancer. Asian Pac J Cancer Prev. 2016;17(10):4577-4581.